Allgemein

Cyntegrity Announces Upcoming Virtual Dialogue on „Responsible AI in Clinical Trials“

Cyntegrity, a front-runner in AI-augmented clinical trial risk management solutions, proudly announces its upcoming virtual conference on "Responsible AI in Clinical Trials," scheduled for November 15 and 16. This groundbreaking event is designed to bridge the knowledge gap and stimulate multistakeholder conversations on the responsible application of Artificial Intelligence in clinical research.

Linda Bunschoten, Cyntegrity’s Chief Marketing Officer, shed light on the event’s unique approach. "Unlike many larger forums that lean towards commercialization, our mission is to instigate genuine dialogue, foster knowledge sharing, and facilitate learning in an intimate setting. This strategy cultivates more real and insightful discussions," she commented.

Artem Andrianov, Ph.D., CEO and founder of Cyntegrity, elaborated on the company’s vision, "We’re on the brink of some incredible changes in clinical trials, thanks to AI. But let’s not get so caught up in the tech that we forget the people it affects. This event is our chance to turn the challenges of ethical AI into opportunities for better healthcare for everyone."

A lineup of esteemed speakers is set to grace the event, such as "The AI Republic" author Danny Goh, Microsoft’s Wole Moses, Professor for Artificial Intelligence Kai Eckert, and Wicked Problem Wizard Nechama Katan. Each will contribute their unique blend of academic and industry insights.

Cyntegrity’s dedication to community-building around this crucial topic is underscored by its regular provision of complimentary workshops to the Life Sciences sector and educational endeavors like the MyRBQM Academy.

Bunschoten stressed the importance of including regulatory perspectives in these dialogues. "Regulators, especially esteemed bodies like the FDA and EMA, are not only welcome but are seen as key contributors to responsible AI. Their engagement with smaller-scale communities and initiatives is crucial to ensure they remain attuned to the pulse of frontline innovations and emerging voices," she articulated.

Cyntegrity invites Clinical Research industry professionals, researchers, and other stakeholders to partake in this enlightening dialogue: https://responsible-ai-event.rbqm.ai/…

Über die Cyntegrity Germany GmbH

Cyntegrity is a leading intelligent risk-based quality management (RBQM) solutions provider in the BioPharma industry, applying risk-based strategies to manage patient safety and data quality, through it’s innovative and highly rated MyRBQM® Portal and MyRBQM® Academy platforms. Through these platforms, Cyntegrity supports sponsors, CROs, and auditors with data science technology and related educational programs to focus clinical operations resources on the locations and activities where they are most needed.

Cyntegrity is a fast-growing scale-up company staffed by an international team of industry experts, representing over 17 nationalities living in 14 countries.

Cyntegrity’s mission is to become the first-choice provider of AI-driven SaaS and PaaS solutions for ICH GCP E6(R2) and E8(R1)-compliant clinical trial risk management and risk-based regulatory oversight and surveillance.

Firmenkontakt und Herausgeber der Meldung:

Cyntegrity Germany GmbH
Altenhöferallee 3
60438 Frankfurt am Main
Telefon: +49 (0) 6192-470-113-50
https://cyntegrity.com/

Ansprechpartner:
Linda Bunschoten
Chief Marketing Officer at Cyntegrity
Telefon: +49 (6192) 470113-50
E-Mail: linda.bunschoten@cyntegrity.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel